Securisyn’s Tech Saves Patients’ Lives and Hospitals’ Bottom Lines - KingsCrowd

Analyst Report: Upgrade for access Securisyn’s Tech Saves Patients’ Lives and Hospitals’ Bottom Lines

Using Securisyn's medical technology, hospitals should be able to both save lives and make better profits.

Company: Securisyn Medical on Republic 2022
Security Type: SAFE
Valuation: $40,000,000
Min Investment: $100
Platform: Republic
Deadline: Dec 31, 2022
Andy Gordon - December 27th

Archaic Technology

Note: This recommendation was co-authored by KingsCrowd Investment Research Analyst Teddy Lyons.

I prefer to stay as far away from hospitals as possible. 

Don’t get me wrong. I appreciate hospitals. But I also know that hospitals are businesses that are concerned with revenue and profit just like any other company. And that means that patient care is not always a top priority. This is America. We live in a capitalist, for-profit society. So I get it. But for some reason, knowing this about hospitals rubs me the wrong way.

I do give hospitals credit for having the most cutting-edge tools at their disposal, which is some consolation. That’s certainly true for imaging and surgical technology. 

But what if I told you that there is an area of patient care where practitioners use tape as the main source of stabilization? Can’t be, right?

Well, that is precisely the case when it comes to the stabilization of breathing tubes used to keep ventilated patients alive. Tape! Let that sink in. Because it’s as bad as it sounds. Tape is so unstable that unplanned extubation (the accidental removal of a breathing tube from an airway) is associated with 33,000 preventable deaths each year in the United States. 

The technology is archaic. In fact, it’s a joke. Somehow, no company has stepped forward to offer a product that can prevent the epidemic of endotracheal tube slippage and unplanned extubation. 

Until now.

The company I’m introducing to you today — Securisyn Medical — has patented a tube stabilization device that solves the life-threatening issues surrounding unplanned extubation and tube slippage. 

For hospitals, this is huge. Any opportunity to lower fatality rates is an obvious reason to purchase a product like SolidAIRity Flex, Securisyn’s flagship breathing stabilization product. 

And because the product never enters the body, Securisyn’s products do not need FDA approval. That’s a big investing risk off the table. 

Pay Annually
and save 17%

This article requires: Edge Pro

Full site access including KingsCrowd's qualitative analyst reports.

49.95 /month
41.58 /annually

What's included

  • Everything in Edge, plus
  • Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
  • Search and filter based on Analyst Reports
  • In-depth risk ratings for every raise

Get access to the first and only premium analytics and rating platform that enables informed startup investments.

Join the KingsCrowd insiders!

Sign up for our 3 minute newsletter with fresh takes on the investments you should know.

We care about the protection of your data. Read our Privacy Policy.